Impairment of Digestive Potential in Multiple Sclerosis Patients and in Osteoporosis Patients


Multiple Sclerosis is a generalized membrane disease leading to a loss of membrane condenser function. Viruses of the measle-distemper group are not sufficiently inactivated in such patients as Cook[ 1] demonstrated with samples taken from the duodenal mucosa of M.S. patients. The reduced charge of the membrane condenser leaves the cell open to immune aggression. This decrease in voltage is followed by degradation of the membrane's structural integrity. It is for this reason that we named the colamine phosphate salts (Calcium, Magnesium and Potassium 2-AEP), the "Membrane Integrity Factor[Trademark]" or "Vitamin Mi[Trademark]." It restores the electrical membrane function and membrane structure. Bone calcium loss, decalcification syndromes, osteoporosis, kidney pyelon infections, fragility of small vessels and other symptoms are a direct result of the membrane impairments when found in M.S. patients.

We have found over the last six years that M.S. patients show a functional impairment of their alveolar gas exchange, with a tendency toward increased carbon dioxide partial pressure in the blood. This again is a side effect of the membrane impairment since the increase in the carbon dioxide partial pressure coincides with the progressiveness of the disease.

Another consequence of membrane impairment in M.S. patients besides Osteoporosis and decalcification syndrome is the malabsorption as reported by Cook.[ 2] Over the years, we have been using the colamine phosphate salts produced by a German pharmaceutical company. We were not seeing the expected improvement in relatively many of the patients (2800 patients so far) when we came to the conclusion that the tightly compressed pills manufactured by the German pharmaceutical company were poorly absorbed in M.S. patients that had membrane impairment. The results from the study by Cook in 1978 supported this conclusion. The poor absorption affected mainly Mg-AEP[R] which is essential for the better membrane fixation of calcium. It is for this reason that we have formulated a new Calcium, Magnesium and Potassium 2-AEP based on a sophisticated manufacturing technique that involves a micro-vortex enteric coating of the granules. In Germany there were approximately fifteen manufacturers of a drug called glibenclamide which is effective in the treatment of diabetes II hyperglycemia. Of those fifteen manufacturers, it was found that only one worked reliably against diabetes (Euglucon[Trademark] Hoechst-Bochringer). The formulation of the new colamine phosphate products comes close to this technology which made Euglucon[Trademark] effective.

In cases of osteoporosis and decalcification syndrome, many of the calcium carrier compounds that are currently being used are in fact, not well absorbed. It has, however, been shown that when Calcium 2-AEP is taken over a long period of time there is a dramatic decrease in the incidence of bone fracturization. Since the application of Calcium 2-AEP began 24 years ago there has been only five broken bones in 2800 M.S. patients. In the years before the application of Calcium 2-AEP 22 out of 100 patients died from irreparable bone fractures.

Calcium 2-AEP enhances bone formation by reactivating the basic collagen texture of the bone and this in turn produces more apatite. This can be compared to fluoride compounds that increase bone density mainly by forming an amorphous calcium agglomerate (as reported by Zichner and Willert[ 3]). This type of structure produced by fluoride therapy does not increase bone stability whereas with Calcium 2-AEP therapy and production of more apatite, bone stability is substantially increased. This phenomenon was observed by dentists in our hospital. They have reported a stronger bone structure in the jaws of M.S. and osteoporosis patients who were treated with Calcium 2-AEP.

With the new technique of the micro-vortex enteric coating of the granules in Calcium 2-AEP and Calcium Arginate, the absorbability is greatly increased even in those cases of malabsorption that are found in M.S. and Osteoporosis patients.

We are now able to test the degree of malabsorption (as first described by Cook[ 2]) with the help of the German Desmoid-Test (Pohl-Boskamp, manufacturer). This is accomplished with a small rubber or plastic bag that contains a dye and is sealed by a string made of natural catgut. If the upper small intestine digests the gut string (which is normal), the urine will turn the color of the dye.

The results of the Desmoid Test on 75 M.S. patients were as follows:

Color positive: four ( 4) normal digestion

Color positive in a repeated assay: three ( 3)

Color positive after about 15-25 hrs: three ( 3) this qualifies as negative

Color Negative: sixty three (63)

The Desmoid Test, therefore, confirms the earlier findings of Cook, et al. The problems of malabsorption in M.S. and decalcification patients can only be overcome by a sophisticated technique of micro-vortex enteric coating of the granule s as in Calcium 2-AEP (Vitamin Mi[Trademark], Membrane Integrity Factor[Trademark]). The clinical evidence for this statement has been well documented and the micro-vortex enteric coated granules in capsule form have been proven to be more effective than the compressed pills.

Drs. Steinhof, Preuss, Heitmann, Perrey and Potrykus at Silbersee Hospital Department of Medicine jointly conducted this Desmoid study.

1. Albert W. Cook et al., "Multiple Sclerosis and Malabsorption," The Lancet, No. 8078, pp-1366, June 14, 1978.

2. Albert W. Cook et al., "Jejunal Viral Antigen in Multiple Sclerosis and Amyotrophic lateral Sclerosis," The Lancet, No. 8008, pp-434, FEb. 19, 1977.

3. L. Zichner and H.G. Willert, "Wie Wirkt Fluor am Skelett," How is Fluoride Working on Bone?), Orthopadische Praxis XII, I, p-46-51 (1976).

4. See also: George Morrissette, "Retrospective Study of the effect of Ca (Mg, K) - AEP in MS Patients," (284 pts. in the study, about 82% improvement/response rate.) Hans Neiper Archive. A. Keith Brewer Sc. Library, Richland Center, W153581.

Dr. H.A. Nieper, Dept. of Medicine, The Paracelsus Silbersee Hospital, Oert Zeweg 24, 3012 Langerhagen, Hannover, Germany


By H.A. Nieper

Share this with your friends